When RON MET TAM in mesothelioma: all druggable for one, and one drug for all?
AffiliationThoracic Oncology Research Group, Labmed Directorate, St. James's Hospital, Dublin, Ireland
MetadataShow full item record
AbstractMalignant pleural mesothelioma (MPM) is an aggressive inflammatory cancer with a poor survival rate. Treatment options are limited at best and drug resistance is common. Thus, there is an urgent need to identify novel therapeutic targets in this disease in order to improve patient outcomes and survival times. MST1R (RON) is a trans-membrane receptor tyrosine kinase (RTK), which is part of the c-MET proto-oncogene family. The only ligand recognized to bind MST1R (RON) is Macrophage Stimulating 1 (MST1), also known as Macrophage Stimulating Protein (MSP) or Hepatocyte Growth Factor-Like Protein (HGFL). In this study, we demonstrate that the MST1-MST1R (RON) signaling axis is active in MPM. Targeting this pathway with a small molecule inhibitor, LCRF-0004, resulted in decreased proliferation with a concomitant increase in apoptosis. Cell cycle progression was also affected. Recombinant MST1 treatment was unable to overcome the effect of LCRF-0004 in terms of either proliferation or apoptosis. Subsequently, the effect of an additional small molecular inhibitor, BMS-777607 (which targets MST1R (RON), MET, Tyro3, and Axl) also resulted in a decreased proliferative capacity of MPM cells. In a cohort of MPM patient samples, high positivity for total MST1R by IHC was an independent predictor of favorable prognosis. Additionally, elevated expression levels of MST1 also correlated with better survival. This study also determined the efficacy of LCRF-0004 and BMS-777607 in xenograft MPM models. Both LCRF-0004 and BMS-777607 demonstrated significant anti-tumor efficacy in vitro, however BMS-777607 was far superior to LCRF-0004. The in vivo and in vitro data generated by this study indicates that a multi-TKI, targeting the MST1R/MET/TAM signaling pathways, may provide a more effective therapeutic strategy for the treatment of MPM as opposed to targeting MST1R alone.
CitationBaird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, et al. When RON MET TAM in mesothelioma: all druggable for one, and one drug for all? Front Endocrinol. 2019;10:89.
JournalFrontiers in Endocrinology
- RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
- Authors: Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R
- Issue date: 2011 Jul 1
- MSP-RON signalling in cancer: pathogenesis and therapeutic potential.
- Authors: Yao HP, Zhou YQ, Zhang R, Wang MH
- Issue date: 2013 Jul
- RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
- Authors: Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, Wu ZG, Tang TM, Fu PF, Wang MH, Yao HP
- Issue date: 2020 Jul
- HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.
- Authors: Ruiz-Torres SJ, Benight NM, Karns RA, Lower EE, Guan JL, Waltz SE
- Issue date: 2017 Aug 29
- MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC).
- Authors: Li C, Morvaridi S, Lam G, Chheda C, Kamata Y, Katsumata M, Edderkaoui M, Yuan X, Nissen N, Pandol SJ, Wang Q
- Issue date: 2019